Clinical trials: Coronary Patient
Coronary Artery Disease
EPC by Intracoronary Injection in Patients With Chronic Stable Angina
Study title:A Study for Testing Safety and Efficacy of the administration of Blood-Borne Autologous Endothelial Progenitor Cells to Alleviate Anginal Symptoms and Myocardial Ischemia in Patients with Severe Anginal Syndrome…
- Trial name
- NCT00384514
- Testing
- VesCell (TM)-Autologous EPCs/Angiogenic Cell Precursors
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- TheraVitae Ltd.
Atrial Fibrillation
Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden
The purpose of the study is to determine whether treatment with BMS-914392 is safe, well tolerated and associated with a reduction of atrial fibrillation burden in patients with paroxysmal atrial fibrillation and permanent…
- Trial name
- NCT01356914
- Testing
- BMS-914392
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage
This study is an opportunity for Boehringer Ingelheim to collaborate with Humana to conduct comparative safety and effectiveness studies of dabigatran and warfarin using real world data from Humana's health plan operations.
- Trial name
- NCT02061748
- Testing
- Observational
- Where
- United States
- Volunteers
- 38,499 people
- Sponsor
- Boehringer Ingelheim
Dilated Cardiomyopathy (DCM), Cardiovascular Diseases
BAG3-DCM Natural History Study
The goal of this international observational study is to learn about the natural history of Dilated Cardiomyopathy (DCM) arising from pathogenic BAG3 variants in adult patients ≥18 years of age.
- Conditions
- Dilated Cardiomyopathy (DCM), Cardiovascular Diseases, Heart Diseases, Genetic Diseases
- Trial name
- NCT07486752
- Volunteers
- 30 people
- Sponsor
- Rocket Pharmaceuticals Inc.
Congestive Heart Failure
Monitoring of Arrhythmias and HRV in Patients With Heart Failure Treated With the CRT Pacemaker Renewal TR2
The objective of this study is to evaluate the prevalence of sustained ventricular and supraventricular rhythm disorders in patients implanted with a CONTAK RENEWAL TR2 ventricular resynchronization therapy (CRT) device
- Trial name
- NCT00180531
- Testing
- Renewal TR2
- Where
- 10 sites in France
- Volunteers
- 500 people
- Sponsor
- Guidant Corporation
Acute Coronary Syndrome
An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)
The TREASURE observational study is designed to address the need to understand the usage pattern of Ticagrelor in real life scenario in large number of ACS (Acute Coronary Syndrome) patients in India.
- Trial name
- TREASURE (NCT02408224)
- Where
- 31 sites in India
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Arrythmia
Importance of Patient´s Satisfaction With Telemedicine Based on Monitoring Systems
Valiosa is a national, multicenter and prospective post market study. The objectives of the study are to generate and validate an instrument to evaluate patient and clinician's satisfaction with remote monitoring and to create…
- Trial name
- VALIOSA (NCT02401659)
- Testing
- CareLinK
- Where
- 4 sites in Spain
- Volunteers
- 187 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Non-small Cell Lung Cancer, Head and Neck Cancer
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03518554
- Testing
- JAB-3068
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
CIN
A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography
The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with moderate to severe renal insufficiency undergoing cardiac…
- Trial name
- NCT00289029
- Testing
- Iopamidol 370 mgI/mL
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Bracco Diagnostics, Inc
Coronary Artery Disease, Everolimus
SPIRIT FIRST Clinical Trial of the Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System
Prospective, randomized, controlled, single-blinded, parallel two-arm, multicenter trial. Test arm: XIENCE V® Everolimus Eluting Coronary Stent System(stent length: 18mm, diameter: 3.0mm) Control arm: Metallic stent (MULTI-LINK…
- Conditions
- Coronary Artery Disease, Everolimus, Vascular Disease, Myocardial Ischemia
- Trial name
- NCT00180453
- Testing
- Coronary artery drug eluting stent placement, Coronary artery stent placement
- Where
- 7 sites in Denmark, Germany and 1 more
- Volunteers
- 60 people
- Sponsor
- Abbott Medical Devices
Heart Failure
Renal Denervation in Patients With Chronic Heart Failure & Renal Impairment Clinical Trial
This is a feasibility study enrolling up to 40 patients in Australia and Europe. The primary aim of the study is to demonstrate the renal denervation with the Symplicity Catheter is safe and determine the evidence of a response…
- Trial name
- SymplicityHF (NCT01392196)
- Testing
- Renal Denervation
- Where
- Australia
- Volunteers
- 39 people
- Sponsor
- Medtronic Vascular
Cardiac Failure, Myocardial Failure
An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic
The purpose of this study is to investigate continuous 8-hour introductions of BMS-986231 in participants with heart failure and weakened heart function given a standard dose of diuretic.
- Conditions
- Cardiac Failure, Myocardial Failure, Congestive Heart Failure, Heart Decompensation
- Trial name
- NCT03730961
- Testing
- BMS-986231, Furosemide
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Essential Hypertension, Left Ventricular Hypertrophy
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e.
- Trial name
- CandLE (NCT00607633)
- Volunteers
- 686 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)
A-Phase: Evaluating patients with chest pain who are receiving approved drugs, to estimate the effectiveness of one type of blood thinner as compared to another type of blood thinner.
- Trial name
- NCT00251576
- Testing
- A-Phase: tirofiban; Z-Phase simvastatin, Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years, Comparator: A-Phase: low molecular weight heparin, unfractionated heparin
- Volunteers
- 4,497 people
- Sponsor
- Organon and Co
Duchenne Muscular Dystrophy
Safety and Efficacy of P-188 NF in DMD Patients
This is an open-label study to evaluate the safety, tolerability and efficacy of daily, subcutaneous dosing with P-188 NF (Carmeseal-MD™) in non-ambulatory boys with Duchenne Muscular Dystrophy (DMD).
- Trial name
- NCT03558958
- Testing
- P-188 NF
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Phrixus Pharmaceuticals, Inc.
Hypercholesterolemia, Coronary Heart Disease
Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis
The purpose of the study is to evaluate the safety and efficacy of dosing with mipomersen for 26 weeks in treating severely hypercholesterolemic patients who are on a maximally tolerated lipid-lowering regimen and who are not on…
- Trial name
- NCT00794664
- Testing
- Mipomersen
- Where
- 27 sites in United States, Canada and 4 more
- Volunteers
- 58 people
- Sponsor
- Kastle Therapeutics, LLC
Heart Failure
Artificial Intelligence-Based Disease Management in the Vulnerable Period of Heart Failure
The study aims to evaluate the effect of AI-based discharge training after acute decompensation of heart failure on the patient's quality of life and to examine the relationship between changes in voice and speech characteristics…
- Trial name
- AIDMy-HF (NCT05544006)
- Where
- Turkey (Türkiye)
- Volunteers
- 76 people
- Sponsor
- Albert Saglik Hizmetleri ve Ticaret A.S.
Cardiovascular Diseases
Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD
To investigate whether a long-term strategy to lower LDL cholesterol with atorvastatin as much as possible will improve prognosis in CHD patients compared with a strategy reflecting current best clinical practice with simvastatin.
- Trial name
- IDEAL (NCT00159835)
- Testing
- atorvastatin, simvastatin
- Where
- 194 sites in Denmark, Finland and 4 more
- Volunteers
- 8,600 people
- Sponsor
- Pfizer
Coronary Artery Disease
NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial
The NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial is a prospective, multi-center, randomized trial. The study compares NeoVas sirolimus-eluting bioresorbable coronary scaffold with XIENCE PRIME Everolimus…
- Trial name
- NCT02305485
- Testing
- NeoVas BCS, XIENCE PRIME EECSS
- Where
- 27 sites in China
- Volunteers
- 560 people
- Sponsor
- Lepu Medical Technology (Beijing) Co., Ltd.
Chronic Heart Failure, CKD Stage 3
Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System
The REFORM-HF study aims to test a new technology, AQUAPASS, designed to assist patients experiencing symptoms of fluid overload due to Heart Failure.
- Trial name
- REFORM-HF (NCT06360380)
- Testing
- AquaPass System
- Where
- 10 sites in United States, Israel
- Volunteers
- 40 people
- Sponsor
- AquaPass Medical Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.